Chinese expert consensus on standardized application of two-dimensional brachytherapy for cervical cancer
Brachytherapy Group of China Society for Radiation Oncology, Gynecological Oncology Group of Chinese Association for Therapeutic Radiation Oncologists, Brachytherapy Special Committee of Chinese Anti-Cancer Association
Abstract：Brachytherapy is an essential part of radical radiotherapy for cervical cancer. At present, two-dimensional brachytherapy is the most frequently adopted approach in China. To standardize the application and implementation of two-dimensional brachytherapy for cervical cancer, the expert consensus was jointly formulated by Brachytherapy Group of China Society for Radiation Oncology (CSTRO), Gynecological Oncology Group of Chinese Association for Therapeutic Radiation Oncologists (CATRO) and Brachytherapy Special Committee of Chinese Anti-Cancer Association (CACA).
Brachytherapy Group of China Society for Radiation Oncology,Gynecological Oncology Group of Chinese Association for Therapeutic Radiation Oncologists,Brachytherapy Special Committee of Chinese Anti-Cancer Association. Chinese expert consensus on standardized application of two-dimensional brachytherapy for cervical cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(9): 718-720.
[1] Chassagne D, Dutreix A, Almond P, et al. Dose and volume specification for reporting intracavitary therapy in gynecology[R]//International Commission on Radiation Units and Measurements. ICRU Report 38. Bethesda, Maryland:ICRU,1985:1-30. [2] Subir N, Beth E, Thomadsen B, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix[J]. Int J Radiat Oncol Biol Phys, 2000, 48(1):201-211. DOI:10.1016/s0360-3016(00)00497-1. [3] Viswanathan AN, Thomadsen B, BerwalS, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I:General principles[J]. Brachytherapy, 2012, 11(1):33-46. DOI:10.1016/j.brachy.2011.07.003. [4] Akila NV, Sushil B, Demanes DJ, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part Ⅱ:High-dose-rate brachytherapy[J]. Brachytherapy, 2012, 11(1):47-52. DOI:10.1016/j.brachy.2011.07.002. [5] Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN clinical practice guidelines in oncology (NCCN guidelines) for cervical cancer. Version 1.2020[EB/OL][2020-04-09]. https://www.nccn.org. 2020-1-14. [6] Assenholt MS, Petersen JB, Nielsen SK, et al. A dose planning study on applicator guided stereotactic IMRT boost in combination with 3D MRI based brachytherapy in locally advanced cervical cancer[J]. Acta Oncol, 2008, 47(7):1337-1343. DOI:10.1080/02841860802266698. [7] Petereit DG, Sarkaria JN, Potter DM, et al. High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer:analysis of tumor recurrence. The university of Wisconsin experience[J]. Int J Radiat Oncol Biol Phys, 1999, 45(5):1267-1274. DOI:10.1016/s0360-3016(99)00262-x. [8] Petereit DG, Sarkaria JN, Chappell R, et al. The adverse effect of treatment prolongation in cervical carcinoma[J]. Int J Radiat Oncol Biol Phys, 1995, 32(5):1301-1307. DOI:10.1016/0360-3016(94)00635-X. [9] Lanciano RM, Pajak TF, Martz K, et al. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation:a Patterns-of-Care study[J]. Int J Radiat Oncol Biol Phys, 1993, 25(3):391-397. DOI:10.1016/0360-3016(93)90058-4. [10] Kubo HD, Glasgow GP, Pethel TD, et al. High dose rate brachytherapy treatment delivery:Report of the AAPM Radiation Therapy Committee Task Group No. 59[J]. Med Phys, 1998, 25(4):375-403. DOI:10.1118/1.598232.
2020, Vol. 29 
